Hearing held by the Subcommittee on Technology. Witnesses include: Raymond G. Kammer, Director, National Institute of Standards and Technology; Dr. Francis S. Collins, Director, National Human Genome Research Institute, National Institutes of Health; Dr. William F. Raub, Deputy Assistant Secretary of Science Policy, Department of Health and Human Services (HHS); and Dr. Michael Watson, Professor of Pediatrics and Genetics, Washington University School of Medicine, Co-Chair, NIH-DoE Task Force of Genetics Testing.
The new science of pharmacogenomics aims to understand how an individual's genetic composition affects his/her response to a specific drug or class of drugs. By studying such characteristics as drug metabolizing enzymes, drug transporter activity, and receptor sensitivity, a pharmacist is better able to prescribe the right drug the first time.If you are pharmacist, resident, or student curious about this new field, start withConcepts in Pharmacogenomics. In this practical guide, you will find an overview of the science behind pharmacogenomics, followed by detailed chapters related to its clinical application and implementation.Features include: case studies in each chapter clinical pearls illustrations of key concepts figures, diagrams, and flow charts for visual learners key points summarized.
This report provides a state-of-the art review of advances in genetic testing and of main international policy concerns drawing from the OECD workshop on "Genetic Testing: Policy Issues for the New Millennium", held in Vienna on 23-25 February 2000.
Publisher description -- The sixteen original essays in this book provide a critical guide to many ethical issues at the heart of genetics technology--and our genetics future. Drawing on fields ranging from medicine and law to religion, health policy, and biotechnology, the essays address the core topics at the heart of current debates: legal, policy, and business dimensions of the genetics revolution; cultural and social implications of genetics; and practical and clinical issues. The essays serve as authoritative guides to current concerns in a wide range of areas, from the impact of genetics on aging and long-term care to the ethics of pharmacogenetics, prenatal screening, and research with children. An epilogue connects ethics discourse to debates on embryonic stem cell research and therapeutic cloning.
There is growing enthusiasm in the scientific community about the prospect of mapping and sequencing the human genome, a monumental project that will have far-reaching consequences for medicine, biology, technology, and other fields. But how will such an effort be organized and funded? How will we develop the new technologies that are needed? What new legal, social, and ethical questions will be raised? Mapping and Sequencing the Human Genome is a blueprint for this proposed project. The authors offer a highly readable explanation of the technical aspects of genetic mapping and sequencing, and they recommend specific interim and long-range research goals, organizational strategies, and funding levels. They also outline some of the legal and social questions that might arise and urge their early consideration by policymakers.